All continuous variables were expressed as mean standard deviation (SD) to summarize central tendency and variability
Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)
What users typically report: Deep sleep is reliably improved Sleep tracker data (for those who use it) typically shows increased deep sleep percentage by this stage Stress resilience during the day Better sleep produces cascading daytime benefits
These products are intended exclusively for laboratory research purposes and are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition
In parallel, A375 cells were seeded in black 96 well plates at a density of 4 10 4 cells/well in a 5% CO 2 incubator overnight at 37 C for 24 h
